Cellular reprogramming of human amniotic fluid cells to express insulin

Area of Science:

• Cell biology
• Regenerative medicine
• Diabetes research

Background:

• Type 1 diabetes treatment faces limitations due to scarce donor islets for transplantation.
• Human amniotic fluid (hAF) contains multipotent progenitor cells with differentiation potential.
• Reprogramming hAF cells offers a promising alternative for generating insulin-producing cells.

Purpose of the Study:

• To assess the feasibility of reprogramming hAF cells into a beta cell phenotype.
• To identify key transcription factors for inducing insulin gene expression in hAF cells.
• To evaluate the therapeutic potential of reprogrammed hAF cells in a diabetic animal model.

Main Methods:

• Developed a DsRed reporter system (DSRE) to monitor insulin promoter activity in hAF cells.
• Utilized lentiviral technology for stable reporter cell line creation.
• Employed combinatorial high-content screening with adenoviral transcription factor expression.
• Assessed beta cell marker expression using RT-qPCR and live-cell imaging.

Main Results:

• Identified an optimal combination of transcription factors to induce insulin gene expression in hAF cells.
• Reprogrammed cells expressed key beta cell transcription factors and proteins.
• Achieved very low-level insulin gene expression, insufficient for therapeutic effect.
• High-content live-cell imaging proved effective for monitoring cellular reprogramming.

Conclusions:

• Human amniotic fluid cells can be reprogrammed to express essential beta cell markers.
• Current reprogramming strategies yield insufficient insulin production for reversing hyperglycemia in diabetic models.
• Further optimization is needed to enhance insulin expression for potential diabetes therapy.